Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Proof-of-Concept Study Evaluating the Safety and Efficacy of ADX-914 in Subjects With Moderate to Severe Atopic Dermatitis

NCT05509023 is registered in ClinicalTrials.gov with Q32 Bio Inc. as lead sponsor.

NCT NCT05509023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05509023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Proof-of-Concept Study Evaluating the Safety and Efficacy of ADX-914 in Subjects With Moderate to Severe Atopic Dermatitis
Lead sponsor
Q32 Bio Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 30, 2022
Completion date
December 31, 2024
Enrollment
102 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis